Akari Therapeutics enters $25M ELOC with White Lion Capital; CFO resigns

Akari Therapeutics Plc

Entered $25M equity line with White Lion Capital; commitment period through Aug 29, 2028.
Pricing options include 97% of lowest price in 2-hour window or 20% discount if price below opening.
CFO Torsten Hombeck resigns effective Oct 10, 2025; will consult through Nov 30 for transition.
Company must file S-1 resale registration within 30 days; Exchange Cap at 19.99% of outstanding shares.
Floor price set at $0.20 per ADS; beneficial ownership limit 4.99% (may increase to 9.99% with notice).

item 1.01item 3.02item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.